The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer


ERDOĞAN M., ÖZKAN E. E. , ÖZTÜRK S. A. , YILDIZ M., ŞENGÜL S. S.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.29, no.3, pp.98-104, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.4274/mirt.galenos.2020.89421
  • Journal Name: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Journal Indexes: Emerging Sources Citation Index, Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.98-104
  • Keywords: Ga-68 PSMA PET/CT, prostate cancer, oligometastasis, SUVmax, THERAPY, BIOLOGY

Abstract

Objectives: In this study, we aimed to investigate whether Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scanning is adequate to predict intermediate risk, high risk, or oligometastatic prostate cancer (PCa) as an initial staging modality.